| Code | CSB-RA003995MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ravulizumab-CWVZ, specifically targeting complement component 5 (C5). C5 is a critical protein in the complement cascade, part of the innate immune system that helps eliminate pathogens and damaged cells. Upon activation, C5 is cleaved into C5a, a potent anaphylatoxin that promotes inflammation, and C5b, which initiates formation of the membrane attack complex (MAC). Dysregulated C5 activation contributes to various complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica spectrum disorder (NMOSD).
Ravulizumab-CWVZ is a long-acting humanized IgG2/4κ monoclonal antibody that binds to C5 and prevents its cleavage, thereby inhibiting both C5a-mediated inflammation and MAC-mediated cell lysis. This biosimilar antibody provides researchers with a valuable tool for investigating complement-mediated pathologies, studying C5 biology, and exploring therapeutic mechanisms in complement-related diseases. It serves as an essential reagent for in vitro and in vivo studies examining complement system function and inhibition.
There are currently no reviews for this product.